An acute randomised trial in 57 sedentary adults with type 2 diabetes found a single HIIT session raised flow-mediated dilation more than moderate continuous exercise, while both lowered post-exercise glucose. PICO summary and expert commentary.
Browsing: Type 2 Diabetes
Clinical evidence summaries for type 2 diabetes, including glycaemic therapies, cardiovascular outcomes, kidney protection, complications, technology, obesity, and long-term safety.
A post-hoc sub-analysis of the open-label PROCEED RCT found ipragliflozin did not improve LV diastolic function overall, with only exploratory subgroup signals. PICO summary and expert commentary.
A single-centre Korean pilot RCT of a physician-led digital education and remote-monitoring platform in type 2 diabetes, where both arms reached the same 3-month HbA1c and the early gain reversed once monitoring stopped. PICO summary and expert commentary.
A pooled analysis of three finerenone trials found a modest reduction in new-onset atrial fibrillation/flutter across the cardio-kidney-metabolic spectrum. PICO summary and expert commentary.
A small secondary analysis of the EDICT randomised trial reports that initial triple therapy was associated with slower carotid intima-media thickness progression and lower liver fat than sequential add-on therapy at matched glycaemic control. PICO summary and expert commentary.
Summary: In a post hoc analysis of three clinical trials spanning the glucose tolerance spectrum, fasting and 1-hour circulating Gremlin…
A secondary cost-consequence and budget impact analysis of the TELE-DD trial found a nurse-led telephone program for nonadherent Type 2 diabetics with comorbid depression became cheaper per glycaemically controlled patient by 12-18 months. PICO summary and expert commentary.
A 2-centre factorial RCT in 273 Chinese adults with type 2 diabetes found the Dnurse app did not significantly improve HbA1c attainment, though systolic blood pressure fell in the app arms. PICO summary and expert commentary.
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 met its equivalence margin for HbA1c reduction against reference dulaglutide. PICO summary and expert commentary.
A small mechanistic RCT (n=34) found ertugliflozin did not increase proximal tubular natriuresis (the primary outcome) but did reduce fluid volume and blood pressure by week 12. PICO summary and expert commentary.